The TAZ-CAMTA1 Fusion Protein Promotes Tumorigenesis via Connective Tissue Growth Factor and Ras–MAPK Signaling in Epithelioid Hemangioendothelioma
Open Access
- 20 April 2022
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 28 (14) , 3116-3126
Abstract
Purpose: A consistent genetic alteration in vascular cancer epithelioid hemangioendothelioma (EHE) is the t(1;3)(p36;q25) chromosomal translocation, which generates a WWTR1(TAZ)-CAMTA1 (TC) fusion gene. TC is a transcriptional coactivator that drives EHE. Here, we aimed to identify the TC transcriptional targets and signaling mechanisms that underlie EHE tumorigenesis. Experimental Design: We used NIH3T3 cells transformed with TC (NIH3T3/TC) as a model system to uncover TC-dependent oncogenic signaling. These cells proliferated in an anchorage-independent manner in suspension and soft agar. The findings of the cell-based studies were validated in a xenograft model. Results: We identified connective tissue growth factor (CTGF) as a tumorigenic transcriptional target of TC. We show that CTGF binds to integrin αIIbβ3, which is essential for sustaining the anchorage-independent proliferation of transformed NIH3T3/TC cells. NIH3T3/TC cells also have enhanced Ras and MAPK signaling, and the activity of these pathways is reduced upon CTGF knockdown, suggesting that CTGF signaling occurs via the Ras-MAPK cascade. Further, pharmacologic inhibition of MAPK signaling through PD 0325901 and trametinib abrogated TC-driven anchorage-independent growth. Likewise, for tumor growth in vivo, NIH3T3/TC cells require CTGF and MAPK signaling. NIH3T3/TC xenograft growth was profoundly reduced upon CTGF knockdown and after trametinib treatment. Conclusions: Collectively, our results demonstrated that CTGF and the Ras-MAPK signaling cascade are essential for TC-mediated tumorigenesis. These studies provided the preclinical rationale for SARC033 (NCI 10015-NCT03148275), a nonrandomized, open-label, phase II study of trametinib in patients with unresectable or metastatic EHE.Keywords
Funding Information
- U.S. Department of Defense IDEA Development Award (RA200178)
This publication has 41 references indexed in Scilit:
- CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosisFibrogenesis & Tissue Repair, 2012
- A novel WWTR1‐CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sitesGenes, Chromosomes and Cancer, 2011
- The Hippo Tumor Pathway Promotes TAZ Degradation by Phosphorylating a Phosphodegron and Recruiting the SCFβ-TrCP E3 LigaseJournal of Biological Chemistry, 2010
- Expression and prognostic significance of THBS1, Cyr61 and CTGF in esophageal squamous cell carcinomaBMC Cancer, 2009
- Anoikis resistance and tumor metastasisCancer Letters, 2008
- TEAD mediates YAP-dependent gene induction and growth controlGenes & Development, 2008
- Discovery and development of sorafenib: a multikinase inhibitor for treating cancerNature Reviews Drug Discovery, 2006
- The RAF proteins take centre stageNature Reviews Molecular Cell Biology, 2004
- Ras GTPases: integrins' friends or foes?Nature Reviews Molecular Cell Biology, 2003
- IntegrinsCell, 2002